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Abstract
Randomized placebo-controlled trials (RCTs) are standard for assessing eﬃcacy and safety of treatments.
We pursued preliminary indications that some factors are associated diﬀerentially with responses to
placebo or drugs in RCTs for bipolar mania. We meta-analysed data from RCTs to assess inﬂuences of
study-site count, subjects’ age, sex distribution, diagnostic subgroups, clinical features, trial-completion
rates, and publication year on mean diﬀerence (MD) in mania ratings between intake and ﬁnal
assessments. In 38 RCTs involving 3812 placebo-treated and 6988 drug-treated patients, symptomatic
improvement was similar in placebo arms of trials of eﬀective (6.77, 95% CI 5.77–7.76) and ineﬀective
(7.61, 95% CI 5.47–8.75) drugs. Lesser placebo responses (MD) and greater drug–placebo diﬀerences
(Hedges’ g) were associated with fewer study sites, younger patients’ age, and male sex. More patients
with initial psychotic features and more trial completion in drug arms were associated with greater drug-
associated improvement (MD) and drug–placebo contrast (Hedges’ g), whereas more mixed-state
diagnoses decreased both measures. Identifying modifying factors can support more eﬃcient and
cost-eﬀective designs of therapeutic trials. In trials for mania, fewer sites may limit placebo response and
enhance drug–placebo contrasts.
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Introduction
Randomized, placebo-controlled, trials (RCTs) are
standard for testing eﬃcacy and safety ofmedical treat-
ments. However, ethical, clinical, and practical con-
cerns arise in the use of placebos, particularly when
they interrupt ongoing active treatment or make sub-
ject recruitment into experimental trials diﬃcult
(Charney et al. 2002 ; Ehni & Wiesing, 2008; Kotzalidis
et al. 2008 ; Vieta & Carne, 2005). Nevertheless, use of
placebos as controls in experimental therapeutic trials
continues to be accepted and even required by some
regulatory agencies including the US Food and Drug
Administration (FDA). Alternative trial designs, such
as comparisons of experimental to established treat-
ments usually require large numbers of subjects in
attempts to detect small diﬀerences. Such comparison
designs also risk random and potentially misleading
ﬁndings of ‘non-signiﬁcant diﬀerences’. Spurious
results are especially likely in trials with limited
quality control in subject selection and clinical ratings,
particularly in disorders in which non-speciﬁc or
‘placebo’ response rates typically are moderately
high, including mania (Charney et al. 2002; Kotzalidis
et al. 2008). With ‘non-inferiority’ trials, there is no
expected diﬀerence in eﬃcacy between test treatments
(null hypothesis), and sample size cannot be guided
by statistical power analysis, so that non-rejection of
the null hypothesis may be inconclusive, even with
large samples.
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As therapeutic innovation in psychiatry increases,
more controlled treatment trials are needed, resulting
in greater pressure to recruit patient-subjects quickly
and eﬃciently in large samples that may vary in
quality control. Accordingly, the costs of conducting
such trials, as well as the major challenges of main-
taining scientiﬁc quality control are increasing, with
the risk of loss of sensitivity and a paradoxical increase
in costs as well as increased assessment variance by
requiring very large samples. Quality control is par-
ticularly diﬃcult in increasingly common inter-
national trials carried out in geographically separate
and heterogeneous sites. These circumstances provide
increasing challenges to limiting variance in subject
recruitment, diagnosis, and ongoing assessment, as
well as limiting typically high dropout rates with loss
of data. Such problems appear to be reﬂected in in-
dications that, even in severe psychiatric disorders
including schizophrenia and mania, clinical change
during placebo treatment has been rising in recent
years (Kemp et al. 2010; Sysko & Walsh, 2007 ; Vieta &
Cruz, 2008). A recent collaborative conference involv-
ing the International Society for CNS Clinical Trials
and Methodology (ISCTM) and the International
Society for CNS Drug Development (ISCDD) reviewed
factors associated with placebo-associated responses
in trials (Kemp et al. 2010). Factors considered
included: longer duration of current acute illness epi-
sodes, eﬀects of ‘rescue’ medications such as seda-
tives, variability in assessments, lack of optimized
drug-dosing, as well as inconsistent medication com-
pliance and protocol adherence (Kemp et al. 2010).
Pardoxically, imperfect control of variance and typi-
cally modest eﬀect sizes (drug–placebo contrasts) in
the conduct of trials encourages larger samples de-
rived from more collaborating sites, but at greater
costs and with greater risk of increasing variance with
the risk of regression-to-the-mean in both placebo and
drug arms of RCTs (Kemp et al. 2010). Such circum-
stances have uncertain impact on the quest for larger
or more stable drug–placebo contrasts. It is also an
ethical truism that larger trials require exposing more
patients to inactive placebo treatment.
We hypothesize that identifying characteristics of
research subjects and of trial designs associated with
smaller placebo responses and larger drug–placebo
contrasts, as well as identifying subgroups that may be
particularly treatment-responsive or -tolerant (or the
opposite), will have value in optimizing trial design.
Such considerations should limit the complexity of
trials and decrease their expense, duration, and the
number of persons exposed to potentially inactive
treatments or placebos, as well as facilitating subject
recruitment and retention (Charney, 2000 ; Charney
et al. 2002 ; Kent & Hayward, 2007 ; Kotzalidis et al.
2008). Moreover, placebo-response rates can inﬂuence
observed drug–placebo diﬀerences in trials, and infer-
ences about eﬃcacy of particular treatments relevant
to rational or evidence-based clinical treatment (Kent
& Hayward, 2007).
In response to the many challenges of including
placebo-controls in treatment trials, we conducted a
meta-analysis of RCTs of single treatments in acute
mania. In this analysis, we identiﬁed clinical and trial-
design factors that may be associated with responses
to randomized placebo or drug treatments. In par-
ticular, we sought factors that might enhance drug–
placebo contrasts, or at least limit placebo response, as
a contribution to improving the design of experimen-
tal therapeutic trials.
Methods
Data sources
We conducted meta-analyses of all available ran-
domized, placebo-controlled monotherapy trials for
acute mania in patients with manic or mixed phases
of type I bipolar disorder (BPD). We identiﬁed re-
ports through computerized searches of the PubMed/
Medline ; ClinicalTrials.gov ; Cochrane Central Regis-
ter of Controlled Trials ; Controlled-trials.com; and
EMBASE/Excerpta Medica databases (search terms:
‘bipolar’, ‘mania’, ‘placebo’, ‘ trial ’, and ‘names’ of
individual anticonvulsant, antipsychotic, or other
drugs tested in mania, up to 12 January 2010). We
extended the search by reviewing bibliographies of
reports identiﬁed, as well as reports of presentations
at meetings of the American Psychiatric Association
(APA), American and European Colleges of Neuro-
psychopharmacology, and the International Confer-
ence on Bipolar Disorder. We also consulted study
investigators and representatives and scientists of
pharmaceutical companies that produce antimanic
agents for leads to other trial reports and for access to
data missing from identiﬁed reports.
Study selection and data extraction
We included only trials involving a placebo and one or
more active treatments or doses, assigned randomly,
to test eﬃcacy among consenting adults diagnosed
with acute mania or mixed states of type I BPD by deﬁ-
nitions in the APA Diagnostic and Statistical Manual
(DSM-III to DSM-IV-TR) or Research Diagnostic
Criteria (RDC) (APA, 2000; Spitzer et al. 1978). We
excluded trials involving patients diagnosed with
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unspeciﬁed BPD (NOS), BPD II, or schizoaﬀective
disorders, and trials permitting use of psychotropic
agents other than modest doses of sedatives or
hypnotics (benzodiazepines or chloral hydrate). For
quality control, required trial data were extracted by
two scientists (A. Yildiz and S. O¨zer).
Information extracted and evaluated included
study-site counts, sample sizes in each trial arm, based
on intent-to-treat (ITT) principles (i.e. patients with at
least one post-randomization assessment), mean age
of subjects, sex distribution, initial diagnosis (mania vs.
manic-depressive mixed state), presence of psychotic
features, baseline illness severity ratings (percent of
maximum attainable mania scale scores), nominal trial
duration, rates of trial completion, source of support,
and year of reporting. The primary outcome of interest
was mean change in mania ratings between intake and
last observation, expressed as mean diﬀerence (MD),
considered separately for drug and placebo arms
of each trial. We also considered drug–placebo diﬀer-
ences in outcomes, expressed as Hedges’ g, based on
standardized MD between changes in mania ratings
with drug vs. placebo. The main secondary outcome
measure was rate of response (proportion of subjects
with o50% improvement in mania ratings) with
drug and placebo (Tohen et al. 2009). Ratings of clinical
change were based on the 11-item Young Mania
Rating Scale (YMRS; maximum score=60) used in
80.4% of trials, or the 11-item Mania Rating Scale
(MRS; maximum score=52), which are similar in
scoring characteristics and ability to detect treatment
eﬀects (Endicott & Spitzer, 1978 ; Vieta, 2003; Young
et al. 1978). We examined the primary outcome
measure (MD for placebo or drugs ; Hedges’ g for
drug–placebo contrasts) for association with site
counts, mean age, percent men, initial diagnosis (%
manic vs. mixed), proportion (%) with psychotic fea-
tures, trial completion rates (%), and publication year.
Meta-analyses
We combined data across trials by meta-analytial
modelling of mean changes in mania ratings during
randomized treatment with placebo or drugs. When
standard deviations (S.D.) for changes in score were not
reported, we estimated them by a standard formula
(Whitley & Ball, 2002). Computed values are shown
with 95% conﬁdence intervals (CIs). Since the studies
analysed involved diﬀerent investigators and varied
environments, we used random-eﬀectsmeta-analytical
modelling, with or without evidence of inter-study
heterogeneity as evaluated with preliminary Q tests
(Borenstein et al. 2009).
We examined potential eﬀects of the previously
stated parameters on the primary, continuous outcome
measures of MD for drug arms and placebo arms; and
Hedges’ g for drug–placebo diﬀerences by using un-
restricted maximum-likelihood, mixed-eﬀects meta-
regression modelling to generate a slope function (b
coeﬃcient) that reﬂects the inﬂuence of each factor on
the corresponding outcome measure (Berkey et al.
1995). MD for change in mania ratings between base-
line and end-point in placebo arms and drug arms
of trials are considered placebo eﬀect and drug eﬀect,
respectively ; Hedges’ g indicates adjusted mean
drug–placebo diﬀerence in change in mania ratings
(treatment eﬀect). To limit risk of false-positive (type I)
errors, we corrected a=0.05 by dividing it with
the number of moderator variables (n=7), requiring
pf0.007 (0.05/7) to establish statistical signiﬁcance.
Trials with negative results (statistical non-
separation of drug vs. placebo) are less likely to be
published than those with statistically signiﬁcant
drug–placebo contrasts. To limit such reporting bias,
we performed a comprehensive literature search and
included data from unpublished reports. Then, we
applied the funnel-plot method (pooled MD vs. its
standard error) to evaluate presence of reporting bias
(Sterne & Egger, 2001). We also estimated Orwin’s fail-
safe N values (number of additional hypothetical
studies with zero-eﬀect required to make the pooled
eﬀects derived from meta-analysis trivial, i.e. eﬀect
sizef0.10) ; larger fail-safe N indicates less likelihood
of publication bias (Orwin, 1983). Finally, we em-
ployed Duval & Tweedie’s trim-and-ﬁll approach to
calculate a best-estimate of unbiased eﬀect size by
removing extremely small studies from the funnel
plot individually until the plot became symmetrical
about the (new) pooled eﬀect size (Duval & Tweedie,
2000). We used Biostat commercial software for meta-
analyses (Comprehensive Meta-Analysis, version 2.2 ;
BioStat Inc., USA).
Results
Characteristics of trials and subjects
We identiﬁed 38 studies yielding 56 comparisons (13
with negative results) of 17 active drugs vs. placebo,
involving a total of 5929 patients randomized to a
placebo [Table 1]. Corrected for duplicate counting of
placebo-arm patients in multi-arm trials, a total of
n=3812 patient-subjects were randomized to placebo
arms of the trials considered, and had at least one post-
randomization assessment during protocol-guided
treatment (ITT samples). Most studies (34/38=89.5%)
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Table 1. Characteristics of randomized, placebo-controlled monotherapy studies in mania
Sites (na)
Randomized ITT sample
Men
(%)
Age, yr
(¡S.D.)
Psychotic
(%)
Mixed
(%)
Completers
(%)
Baseline mania
(% max)
Mania improvement
(%)
SourceTotal PBO Total PBO Rx PBO Rx PBO Rx PBO
Aripiprazole
56 270 134 259 130 47.0 41.0¡11.7 – 38.7 39.7 40.3 46.4 47.1 38.8 35.8 El Mallakh et al. (2010)
56 265 134 257 130 49.1 40.0¡11.5 – 39.2 42.7 40.3 46.6 47.1 35.8 35.8 El Mallakh et al. (2010)
38 262 132 243 120 43.5 40.5¡12.2 25.7 32.8 41.5 21.2 47.0 49.5 29.1 11.4 Keck et al. (2003a)
42 330 165 317 163 51.6 39.7¡11.0 21.8 38.2 44.2 47.3 47.5 48.2 44.4 31.2 Keck et al. (2009)
29 272 135 268 132 48.5 38.8¡11.5 13.1 41.5 54.7 51.9 48.0 47.4 43.4 25.3 Sachs et al. (2006)
59 320 153 318 152 44.7 40.4¡11.9 10.6 19.4 75.4 71.2 46.7 47.2 42.8 34.3 Young et al. (2009)
Asenapine
70 283 98 277 94 49.5 38.6¡12.4 36.8 31.1 67.0 58.2 49.0 47.2 48.3 38.2 McIntyre et al. (2009a)
64 298 104 292 103 55.7 39.1¡12.0 29.1 30.2 67.0 58.2 47.2 48.3 46.3 25.5 McIntyre et al. (2009b)
Carbamazepine
24 204 103 192 98 52.5 38.0¡11.0 – 52.9 49.5 44.7 44.3 45.5 32.8 18.9 Weisler et al. (2004)
25 239 117 235 115 70.3 37.0¡11.0 – 20.9 65.6 54.7 47.4 46.6 53.0 25.5 Weisler et al. (2005)
Cariprazine
29 238 120 236 118 63.3 38.5 – – 63.6 61.9 51.0 50.3 43.5 23.8 Knesevich et al. (2009)
Haloperidol
49 200 101 198 100 36.9 42.9 41.9 0.00 77.8 60.4 53.8 55.2 48.6 25.1 McIntyre et al. (2005)
20 284 140 282 138 52.5 39.0 32.0 0.00 89.0 85.0 53.5 52.5 47.0 29.8 Smulevich et al. (2005)
33 260 88 258 88 57.5 37.9¡13.0 32.7 15.4 71.3 50.0 59.0 60.2 51.9 19.5 Vieta et al. (2010b)
59 318 153 313 152 45.0 40.9¡12.0 x9.40 17.9 73.3 71.2 46.0 47.2 46.5 34.3 Young et al. (2009)
16 – – 117 97 – – – – – – – – – 6.8 Katagiri et al. (2010)
Lamotrigine
47 180 95 179 95 52.8 37.2¡10.7 41.7 22.2 62.4 64.2 50.8 49.8 35.2 36.7 Goldsmith et al. (2003)
Licarbazepine
28 324 163 313 158 53.4 40.0¡11.6 36.7 36.7 63.4 68.7 45.8 45.7 33.5 30.3 Novartis (2007)
Lithium
9 110 74 107 72 61.8 39.1¡10.6 22.7 56.0 38.9 36.5 52.0 54.1 34.3 14.4 Bowden et al. (1994)
38 195 97 193 95 58.5 40.1 28.5 0.00 85.7 69.1 55.5 56.7 45.6 19.7 Bowden et al. (2005)
47 131 95 131 95 51.9 39.4¡12.3 39.7 22.9 44.4 64.2 50.4 49.8 40.8 36.7 Goldsmith et al. (2003)
42 325 165 318 163 52.3 39.7¡10.9 24.6 37.5 48.8 47.3 49.0 48.2 40.9 31.2 Keck et al. (2009)
40 224 111 224 111 46.0 42.5¡13.5 29.5 14.7 74.3 73.9 50.2 50.0 42.9 25.7 Kushner et al. (2006)
40 226 112 226 112 38.1 41.5¡11.5 19.5 10.2 81.6 86.6 51.2 52.8 45.0 26.5 Kushner et al. (2006)
Olanzapine
70 303 98 297 94 54.5 38.3¡11.7 33.7 31.7 78.5 58.2 49.5 47.2 54.2 38.2 McIntyre et al. (2009a)
64 295 104 291 103 56.3 39.8¡11.7 29.2 32.3 79.6 61.5 47.7 48.3 48.6 25.5 McIntyre et al. (2009b)
16 139 69 136 66 51.8 39.5¡11.0 53.2 17.3 61.4 34.8 47.8 46.1 35.8 17.6 Tohen et al. (1999)
24 115 60 110 56 49.6 38.7¡10.4 55.7 42.6 61.8 41.7 47.9 49.1 51.4 27.6 Tohen et al. (2000)
42 320 105 300 99 48.3 40.1¡12.4 0.00 29.0 74.0 73.3 39.7 39.2 39.5 35.5 Tohen et al. (2008)
16 – – 201 97 – – – – – – – – 12.6 6.80 Katagiri et al. (2010)
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Paliperidone
44 236 121 235 121 55.7 39.8¡11.2 22.1 33.2 65.2 58.7 47.0 48.0 49.3 9.90 Berwaerts et al. (2009)
44 233 121 233 121 53.6 39.5¡11.3 25.3 37.3 63.4 58.7 47.7 48.0 33.6 9.90 Berwaerts et al. (2009)
44 240 121 239 121 54.4 39.4¡11.2 23.0 32.6 58.0 58.7 46.5 48.0 41.9 9.90 Berwaerts et al. (2009)
52 300 105 294 104 56.1 39.4¡10.6 18.0 34.0 82.1 61.9 45.5 44.2 48.4 27.9 Vieta et al. (2010a)
Quetiapine
38 204 97 202 95 56.9 36.7 29.7 0.00 90.7 69.1 54.5 56.7 44.7 19.7 Bowden et al. (2005)
48 316 161 308 159 – – – – – – – – – – AstraZeneca (2010)
49 203 101 201 100 36.8 41.7 42.8 0.00 64.7 60.4 56.7 55.2 36.1 25.1 McIntyre et al. (2005)
52 298 105 296 104 57.4 38.5¡10.5 22.6 38.5 78.8 61.9 46.0 44.2 42.4 27.9 Vieta et al. (2010a)
Risperidone
20 259 125 246 119 56.8 38.8¡12.1 42.5 0.00 56.0 41.6 48.5 48.7 36.4 16.4 Hirschfeld et al. (2004)
8 291 145 286 142 62.1 35.1¡17.1 59.3 4.50 89.0 70.8 61.8 62.5 61.2 28.0 Khanna et al. (2005)
20 294 140 291 138 52.4 40.4¡13.1 32.7 0.00 90.3 85.0 52.2 52.5 44.4 29.8 Smulevich et al. (2005)
Tamoxifen
1 66 31 58 26 48.5 34.8¡12.3 66.7 6.10 82.9 67.7 64.3 62.0 43.0 x12.9 Yildiz et al. (2008)
1 16 8 16 8 87.5 35.4¡7.80 50.0 31.3 50.0 62.5 50.5 40.5 60.4 x19.2 Zarate et al. (2007)
Topiramate
2 314 100 308 99 46.8 38.7¡11.0 27.3 53.2 58.9 72.0 48.7 47.2 27.6 27.2 Kushner et al. (2006)
2 215 106 213 106 63.4 40.5¡11.5 33.3 34.3 56.0 73.6 50.7 49.2 16.8 21.7 Kushner et al. (2006)
40 331 111 326 111 50.3 42.3¡13.7 29.4 15.0 70.0 73.9 50.8 50.0 19.7 25.7 Kushner et al. (2006)
40 228 112 227 112 37.9 40.5¡12.0 25.1 11.5 87.1 86.6 51.3 52.8 26.6 26.5 Kushner et al. (2006)
Valproate
9 143 74 139 72 54.5 39.7¡11.4 24.5 62.4 52.2 36.5 52.2 54.1 34.0 14.4 Bowden et al. (1994)
99 377 185 364 177 57.4 37.6¡10.5 20.6 43.7 57.8 51.9 51.2 51.2 44.7 33.8 Bowden et al. (2006)
29 225 78 222 78 51.4 39.1¡11.4 40.1 31.5 17.0 17.9 63.3 63.5 30.7 25.8 Hirschfeld et al. (2010)b
9 36 19 36 19 72.2 37.2¡13.3 – 0.00 23.5 21.1 47.0 47.7 40.5 x0.60 Pope et al. (1991)
42 306 105 285 99 49.1 39.9¡12.3 0.00 29.5 75.1 73.3 39.8 39.2 34.3 31.5 Tohen et al. (2008)
Verapamil
1 32 15 20 12 59.4 36.2¡10.6 71.9 6.30 17.6 40.0 55.8 50.0 3.80 5.00 Janicak et al. (1998)
Ziprasidone
24 210 70 197 66 54.3 38.0¡10.5 45.7 35.5 53.6 44.3 51.9 51.3 45.9 29.2 Keck et al. (2003b)
23 206 66 202 65 50.7 39.0¡11.6 31.2 40.8 60.7 54.5 50.4 50.8 42.4 21.3 Potkin et al. (2005)
33 266 88 264 88 59.4 37.7¡12.7 33.1 18.4 66.9 50.0 56.9 60.2 35.2 19.5 Vieta et al. (2010b)
ITT, Intent-to-treat ; MRS, Mania Rating Scale ; PBO, placebo ; Rx, study drug; S.D., standard deviation ; YMRS, Young Mania Rating Scale.
a For studies not reporting actual site numbers, they are estimated as twice that of the reported number of countries.
b A negative trial of divalproex extended release (ER) against placebo.
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were multi-centre collaborations with a large average
(¡S.D.) site count [29.7¡18.9 (range 1–70) sites/trial],
and the same proportion were sponsored by
manufacturers of drugs tested.
Outcomes with eﬀective vs. ineﬀective drugs
Improvements in mania ratings in placebo arms of the
56 trials were 6.92 (95% CI 6.02–7.82) scale points.
Eﬀect-sizes in placebo arms were similar in the 48
trials of 13 drugs with signiﬁcant overall drug–placebo
contrasts (aripiprazole, asenapine, carbamazepine,
cariprazine, haloperidol, lithium, olanzapine, paliper-
idone, quetiapine, risperidone, tamoxifen, valproate,
ziprasidone : pooled MD=6.77, 95% CI 5.77–7.76), and
seven trials of four drugs with non-signiﬁcant overall
drug–placebo contrasts (lamotrigine, licarbazepine,
topiramate, verapamil : pooled MD=7.61 ; 95% CI
5.47–9.75 ; Table 1). Pooled eﬀects in drug arms of the
trials involving eﬀective drugs (MD=12.7, 95% CI
12.0–13.4) were nearly twice as large as the placebo
eﬀects noted above. Improvements in mania ratings in
drug arms of the ineﬀective treatments were 7.31 (95%
CI 5.35–9.27), indicating 1.7-fold superior improve-
ment in successful vs. unsuccessful trials.
Also based on meta-analytical pooling, the overall,
secondary outcome measure of responder rate (im-
proving o50%) was substantial over 3 wk, at 30.8%
(95% CI 28.6–33.2) for all placebo-treated patients. For
trials involving eﬀective drugs, pooled responder rates
were 48.3% (95% CI 46.2–50.4) in drug arms and
30.7% (95% CI 28.1–33.3) in placebo arms – a 1.6-fold
diﬀerence. The pooled responder rate in drug arms
of ineﬀective agents was much lower, as expected,
at 30.8% (95% CI 26.2–35.9), and close to the corre-
sponding placebo-associated responder rate of 31.6%
(95% CI 26.6–37.2). Notably, however, placebo re-
sponder rates in trials of eﬀective and ineﬀective drugs
(agents with non-signiﬁcant overall drug–placebo con-
trasts) were nearly identical (30.7%, 95% CI 28.1–33.3
vs. 31.6%, 95% CI 26.6–37.2, respectively).
These ﬁndings indicate that most of the contrast in
outcomes of trials of apparently eﬀective vs. ineﬀective
agents was due to marked diﬀerences in drug re-
sponse, and that diﬀerences in placebo responses were
minor.
Factors associated with placebo responses
Factors of interest were tested for association with
placebo eﬀect based on changes in mania ratings
(MD) in all placebo-treatment trial arms for which
data were available, and included only once in the
meta-regression modelling (Tables 2 and 3). For
comparison, we considered the same factors for associ-
ation with drug eﬀect (also based on MD for change in
mania ratings) as well as treatment eﬀect (based on
Hedges’ g for eﬀects of drug vs. placebo). For testing
those associations of candidate factors with drug eﬀect
and treatment eﬀect we considered only the 13 drugs
found signiﬁcantly more eﬀective than placebo in a
meta-analysis of individual drugs for bipolar mania
(Yildiz et al. 2010), in order to avoid potential con-
founding by drug ineﬀectiveness, which would inﬂu-
ence the drug-associated beneﬁt as well as observed
drug and placebo diﬀerences. Regression modelling of
drug eﬀect involved only patients in drug arms,
whereas modelling of treatment eﬀect involved
patients in both drug and placebo arms. However, re-
ported proportions of patients given active drugs who
completed each trial were also tested for association
with treatment eﬀect. Since most of the studies did not
report subjects ’ ages in each treatment arm separately,
we used average age for entire study samples in
corresponding regression models. Since seven pre-
selected covariates were tested by meta-regression,
statistical signiﬁcance was set at two-tailed a=0.007.
Meta-regression modelling suggested that a lower
number of collaborating study sites was strongly
associated with lesser placebo-induced improvement
of mania ratings (MD), and greater drug–placebo con-
trasts (Hedges’ g) (see Fig. 1). Of note, more study sites
corresponded to larger patient samples, and with
larger placebo eﬀects (in 38 trials ; b=+0.06, 95% CI
0.04–0.08, z=6.47, p<0.0001). Notably, however, site
counts had no apparent association with drug-asso-
ciated improvements in mania ratings (MD). Male sex
was associated with lesser placebo eﬀects, and greater
treatment eﬀects. On the contrary, younger mean age
was associated with lesser placebo eﬀects and greater
drug-associated improvements, and correspondingly
greater drug–placebo contrasts. Diagnostic subgroups
(mania with or without psychotic features or manic
vs.mixed states) had no apparent inﬂuence on placebo
eﬀects overall, although outcomes were rarely re-
ported separately for such subgroups. However, pres-
ence of psychotic symptoms increased both observed
eﬀects of treatment over placebo and drug-associated
beneﬁt, whereas the proportion of cases with mixed
state decreased both measures (Tables 2 and 3).
More trial completers (lower dropout rates) in
placebo arms was not related to improvements with
placebo, but higher proportion of trial completion
in drug arms was associated with both greater drug-
associated beneﬁt and drug–placebo contrast or treat-
ment eﬀect (Tables 2 and 3). No outcome was asso-
ciated with publication year, and there were too few
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Table 2. Association of factors with changes in mania ratings with placebo or drug (MD), and drug vs. placebo contrasts (Hedges’ g), in randomized, monotherapy trials for
antimanic eﬀects
Factors
Placebo eﬀect (MD) Drug eﬀect (MD) Drug-placebo contrast (Hedges’s g)
N
Slope
(%, 95% CI) z Q model p N
Slope
(%, 95% CI) z Q model p N
Slope
(%, 95% CI) z Q model p
More collaborating
sites (na)
38 +0.11 4.67 21.8 <0.0001 48 x0.02 x0.80 0.64 0.425 48 x0.007 x3.79 14.4 0.0002
(+0.06 to+0.15) (x0.06 to+0.03) (x0.01 tox0.003)
Age (yrb) 36 +0.92 3.07 9.44 0.002 46 x0.69 x2.99 8.96 0.003 46 x0.09 x4.03 16.2 0.00006
(+0.33 to+1.15) (x1.15 tox0.24) (x0.13 tox0.04)
More men (%) 35 x0.18 x3.04 9.23 0.002 46 +0.08 2.28 5.19 0.023d 46 +0.02 3.49 12.2 0.0005
(x0.29 tox0.06) (+0.01 to+0.16) (+0.007 to+0.03)
More with psychotic
features (%)
31 x0.08 x2.20 4.83 0.028d 40 +0.10 4.22 17.8 0.00002 40 +0.85 3.91 15.2 0.00009
(x0.16 tox0.009) (+0.06 to+0.15) (+0.43 to+1.28)
More mixed
state (%)
35 +0.03 0.90 0.81 0.368 45 x0.07 x3.26 10.6 0.001 45 x0.59 x2.92 8.51 0.004
(x0.04 to+0.10) (x0.12 tox0.03) (x0.99 tox0.19)
Trial completers (%) 36 +0.05 1.45 2.10 0.147 46 +0.08 3.99 15.9 0.00007 46 +0.41 1.89 3.58 0.059
(x0.02 to+0.11) (+0.04 to+0.13) (x0.01 to+0.83)
Trial completers :
drug arms (%)
– – – – – 46 +0.08 3.99 15.9 0.00007 46 +0.006 2.86 8.20 0.004
(+0.04 to+0.13) (+0.002 to+0.009)
Publication year
(without outliers)c
36 +0.37 4.86 23.6 <0.0001 46 +0.12 1.13 1.28 0.258 46 x0.02 x1.82 3.32 0.068
(+0.22 to+0.52) (x0.09 to+0.32) (x0.03 to+0.001)
MD, Mean diﬀerence ;N, number of comparisons included in corresponding regression models.Qmodel indicates the amount variance or heterogeneity in eﬀect sizes predicted by
the model. Eﬀect-size measure is MD for placebo eﬀects and drug eﬀects ; and Hedges’ g for drug–placebo contrast. Only eﬀective drugs were considered for drug eﬀect and
drug–placebo contrast, but all available placebo arms were included for placebo eﬀect.
a For studies not reporting actual site numbers, they are estimated as twice that of the reported number of countries.
bMean age for the study sample was the moderator variable used for all three outcomes.
cMeta-regression results after exclusion of outliers (two single-site tamoxifen trials with worsening of mania ratings with placebo).
d Indicates non-signiﬁcance after correction for multiple comparisons (adjusted p=0.05/7=0.007).
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trials not supported ﬁnancially by pharmaceutical
manufacturers to test eﬀectively for potential eﬀects of
sources of study support. However, exclusion of two
small, academic, non-industrial, single-site trials with
unusually low placebo eﬀects led to a secular associ-
ation of rising placebo eﬀects in more recent years, as
well as a secular eﬀect of rising numbers of collabor-
ating sites/trials (Fig. 1).
Publication bias
Examination of funnel plots of the primary outcome
(MD in placebo arms of trials vs. its standard error)
Table 3. Factors associated with change in mania ratings in placebo arms and drug arms, and drug–placebo contrasts
Factors
Mania improvement with treatment
Drug–placebo
contrastsPlacebo Drug
More collaborating sites (na) Increased No eﬀect Decreased
More with psychotic features (%) No eﬀect Increased Increased
Age (yrb) Increased Decreased Decreased
More men (%) Decreased No eﬀect Increased
More mixed-state diagnoses (%) No eﬀect Decreased Decreased
Trial completers (%) No eﬀect Increased No eﬀect
Trial completers : drug arms (%) – Increased Increased
Publication year (without outliers)c Increased No eﬀect No eﬀect
Only eﬀective drugs (>placebo) were considered for drug eﬀects and drug–placebo diﬀerences (in 40–48 randomized, mono-
therapy trials), but all available placebo arms were included for placebo eﬀect (31–38 trials ; unmatched numbers owing to
multiple active treatments in some trials). Improvement is based on mean diﬀerence for placebo eﬀects and drug eﬀects, and
Hedges’ g for drug–placebo contrasts.
a For studies not reporting actual site numbers, they are estimated as twice that of the reported number of countries.
bMean age for the study sample was the moderator variable used for all three outcomes.
c There were no signiﬁcant associations between publication year and any eﬀect measure. However, exclusion of outliers
(two single-site tamoxifen trials with worsening of mania ratings with placebo) indicated rising placebo-related improvements
in recent years.
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Fig. 1. Improvement in mania ratings vs. the number of collaborating sites in randomized, placebo-controlled trials in manic
or mixed bipolar disorder patients. (a) Improvement with placebo treatment (mean diﬀerence between intake and end-point)
for all 38 studies (Q model=21.8, p<0.0001). (b) Eﬃcacy (Hedges’ g for diﬀerence between drug- and placebo-associated
changes) for 48 comparisons involving eﬀective drugs only (Q model=14.4, p=0.0002). (c) For illustration, there was an
expected, strong secular trend (correlation) of sites/trial and year of reporting (r=0.587, p<0.0001) ; two single-site tamoxifen
trials reporting worsening with placebo treatment were excluded.
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indicated publication bias (Kendall’s t=x0.26, z=
2.31, p=0.02). Orwin’s fail-safe N was 2793, indicating
that a very large number of studies with zero eﬀect
would need to be added to produce a trivial outcome,
and that is very unlikely to have arisen by omission of
overlooked reports. Finally, Duval & Tweedie’s trim-
and-ﬁll method did not identify any aberrant studies,
and the summary eﬀect remained unchanged (MD=
6.92, 95% CI 6.03–7.81).
Discussion
This is the ﬁrst meta-analytical evaluation of patient-
characteristics or other trial-design factors for associ-
ation with placebo and drug responses and drug–
placebo contrasts (eﬀect sizes) in RCTs for mania.
After diligent searching to identify all available trials,
we considered RCTs involving DSM-III or DSM-IV
BPD patients in acute manic or mixed states, ran-
domized to the placebo arms or drug arms of 38
studies with 56 drug–placebo contrasts, and reported
on drug eﬃcacy previously (Yildiz et al. 2010). These
RCTs indicated 13 eﬀective (with statistically superior
overall outcomes over placebo: 49 contrasts) and four
ineﬀective (seven contrasts) candidate drugs. Factors
associated with lesser placebo eﬀects included:
(a) fewer collaborating sites, (b) younger patients, and
(c) higher proportion of men in placebo arms (Tables 2
and 3). Since some of these factors are potentially
modiﬁable, their consideration in the design of treat-
ment trials may help to limit sample sizes, placebo
exposure, trial failures, ﬁnancial costs, and generally
yield trials that are more eﬃcient and attractive to
patients, their families, and physicians.
To help with power and sample-size estimates for
future treatment trials in mania, we considered re-
sponses following randomization to placebo or drug
in 49 trials of the 13 eﬀective antimanic agents. In these
successful trials, the meta-analytically pooled MD be-
tween initial and ﬁnal mania ratings was 6.77 scale
points for placebo arms (n=3199), and 12.7 for drug
arms (n=6075), indicating nearly 2-fold superiority of
eﬀective drugs over placebo. In secondary analyses,
pooled responder rates (% of patients showingo50%
improvement in mania ratings) were 30.7% (n=2944)
with placebo and 48.3% (n=5827) with eﬀective drugs,
a somewhat lesser (1.6-fold) contrast. This moderate
absolute diﬀerence of 17.6% in the responder rates
with drug vs. placebo is similar to an estimate of 18%
(41% to drug vs. 24% to placebo) in 38 RCTs involving
7323 participants for schizophrenia (Leucht et al. 2009).
In earlier reviews of eight (Keck et al. 2000) and 21
(Sysko & Walsh, 2007) RCTs in acute mania, reported
placebo responder rates averaged 23.0% and 31.2%,
respectively, or close to our meta-analytical estimate
of 30.8% (95% CI 28.6–33.2) across 38 studies with
56 drug–placebo contrasts (Yildiz et al. 2010).
An initially observed association between presence
of psychotic symptoms and lesser placebo-induced
improvements in mania ratings was not signiﬁcant
after correction for multiple comparisons. Yet, con-
current psychotic symptoms in mania seemed to en-
hance drug-associated beneﬁt as well as drug–placebo
contrasts (Tables 2 and 3). Moreover, a higher pro-
portion of cases diagnosed with manic-depressive
mixed states resulted in lesser treatment and drug
eﬀects, with no apparent eﬀect on placebo-induced
improvements in mania ratings (Tables 2 and 3). These
observations regarding mixed states suggest a sub-
group that is particularly diﬃcult to treat, especially
with an antimanic monotherapy, and a subgroup
that may not appropriately be combined with mania
(Baldessarini et al. 2010). Paradoxically, although
mixed states often are more severe or clinically chal-
lenging than relatively pure mania, their mania rating
scores are often lower. This impression was sustained
in the present ﬁndings, in that baseline mania ratings
were lower with higher proportions of mixed-state
patients in 52 trials with available data (b=x0.10, 95%
CI x0.13 to x0.06, z=x5.19, p<0.0001), with lesser
corresponding improvements with drugs in 46 of the
trials (b=+0.26, 95% CI 0.13–0.40, z=3.80, p=0.0002).
The observed impact of mixed states on trial outcomes
suggests that such patients should be excluded from
mania trials, or at least considered separately, ideally
with assessments of depressive as well as manic
symptoms (Baldessarini et al. 2010). In general, we
favour consideration of subgroups within trials in
order to identify patients who are particularly re-
sponsive or tolerant to particular treatments (or not),
as well as trials that continue to syndromal remission,
and so can better diﬀerentiate speed of eﬀect from
actual eﬃcacy.
Some observers have challenged the ﬁndings of
available clinical trials on mania because of variable or
low baseline severity of mania ratings among patients
included. Initial mania scores in identiﬁed trials con-
sidered in this study were 39.2–65.4% of maximum
attainable scores, and fewer than half of the trials in-
volved baseline mania scores of o50% of maximum
attainable scores. As we reported previously, greater
initial manic symptom severity did not enhance ob-
served drug–placebo contrasts, but instead, ampliﬁed
beneﬁt from the drugs selectively (Yildiz et al. 2010).
This association may reﬂect a more treatment-
sensitive clinical subtype, or, more likely, the technical
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eﬀect of greater apparent improvement with higher
initial severity scores. That is, the ‘law of initial
values’ (more deviant initial assessments tend to yield
greater change with interventions) may well apply to
experimental therapeutics (Benjamin, 1963).
When the present ﬁndings are considered together,
they suggest a proﬁle of manic patients less likely to
improve with a placebo, or with greater drug–placebo
contrasts, i.e. a greater likelihood of a successful trial
outcome. Such characteristics included: (a) trials with
fewer study sites (a particularly strong eﬀect, pre-
sumably reﬂecting better quality control, and with
fewer subjects), (b) younger age, (c) male sex, and
(d) psychotic features. In addition, more completion of
drug treatments was associated with greater beneﬁt
from drug and enhanced drug–placebo contrast.
A particularly notable ﬁnding of this study is that
improvement during placebo treatment was substan-
tially and selectively smaller with fewer collaborating
sites. It challenges the recent trend towards more
sites/trials (Fig. 1). Indeed, some single-site trials in
mania have reported very slight improvement, or even
worsening with placebo treatment (Pope et al. 1991;
Yildiz et al. 2008 ; Zarate et al. 2007). With such rare
small trials omitted (Yildiz et al. 2008 ; Zarate et al.
2007), we found evidence of a secular trend for in-
creasing placebo eﬀects over time, probably as a
manifestation of rising numbers of study sites and
patient-subjects. Further meta-regression after ex-
clusion of the rare single-site studies with particularly
small placebo eﬀects (Yildiz et al. 2008 ; Zarate et al.
2007), veriﬁed the observed associations between
higher numbers of collaborating study sites and
greater placebo-induced improvement in mania rat-
ings (36 trials ; b=+0.06, 95% CI 0.03–0.10, z=3.66,
p=0.00025), as well as smaller drug–placebo contrasts
(46 trials ; b=x0.05, 95% CI x0.009 to x0.002,
z=x2.86, p=0.004). Improvements observed during
treatment with a placebo may reﬂect the natural
course of a time-limited acute illness like mania, vari-
ance in relatively non-speciﬁc interventions related to
clinical management, regression to mean outcome
ratings, as well as an hypothesized ‘placebo eﬀect’
itself (Klosterhalfen & Enck, 2006). Yet, given the large
variance in placebo responses in the trials considered
here, despite nominally similar patients and diagnos-
tic and assessment methods, it is likely that other fac-
tors are also involved. We propose that that ‘noise’,
arising from local and individual variation in the ap-
plication of diagnostic and assessment methods and
diﬃculties in maintaining high levels of inter-rater
and inter-site reliability across geographically and
culturally diverse sites tends to promote regression to
average outcome ratings, as a major determinant of
placebo response. We suggest that a simple means of
mitigating such eﬀects may be to employ fewer and
more homogenous collaborating sites with better con-
trol over diagnostic and symptom assessments.
Although, the available data were not adequate to
support a conclusive assessment, it is also possible that
the sources of ﬁnancial support for trials may aﬀect
their outcome. Most of the acute treatment trials in
mania or mixed states identiﬁed for this study were
sponsored by the manufacturers of the drugs tested,
and only four were supported by non-proﬁt-making
organizations. Meta-analytically pooled improvement
in mania ratings with placebo treatment in 34 indus-
try-sponsored trials was 7.71 (95% CI 7.08–8.35), com-
pared to a far lower value ofx2.92 (95% CIx5.68 to
x0.16) in only four trials with non-industry sponsor-
ship. For drugs with signiﬁcant overall drug–placebo
contrasts, eﬀect sizes in drug arms were comparable in
45 industry-sponsored trials (pooled MD=12.5, 95%
CI 11.8–13.3), and three non-industry-sponsored trials
(pooled MD=15.8, 95% CI 12.1–19.6). The small
number of non-industry-sponsored trials obviates a
meaningful statistical comparison, the ﬁndings sug-
gest that industrial funding was associated with rela-
tively large placebo-related, but not with drug-related
beneﬁts in trials in acute mania. In turn, this eﬀect may
reﬂect the relatively larger numbers of sites and sub-
jects in the pharmaceutical-sponsored trials.
Several limitations of this study should be noted.
Randomization can protect against many subject
selection biases in individual studies but not in meta-
regressions (Borenstein et al. 2009). As such, identiﬁed
associations between study-level moderator variables
and eﬀect sizes are observational results, and cannot
be presumed to be deﬁnitive. Further meta-analytical
evaluation of identiﬁed categorical factors (young/
old, male/female, manic/mixed, psychotic/non-
psychotic, completer/non-completer) on the outcome
measures was not possible since individual studies
did not separately report on these potentially import-
ant subgroups. Similarly, dosing of rescue medica-
tions, exact durations of pre-randomization washout
of previous treatments, and days in hospital during
trials, as well as such clinical details as the numbers,
types, durations, and severity of episodes of previous
illness per study arm were not reported in most trials.
We therefore, strongly encourage the inclusion of such
information, with responses to drug and placebo in
subgroups in future studies of acute mania and other
major disorders.
In conclusion, meta-analysis and meta-regression
modeling based on 56 comparisons of candidate drugs
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with placebo controls in 38 RCTs involving diverse
BPD I patients in acute episodes of mania or mixed
manic-depressive states indicated that a smaller num-
ber of collaborating sites was strongly associated with
lesser responses to placebo treatment, with little in-
ﬂuence on responses to eﬀective drugs. We propose
that this aspect of trial design is readily modiﬁed, and
should improve the eﬃciency of RCTs, at least for
mania. Further research on this, and other indicated
factors may lead to more cost-eﬀective and feasible
trials, exposure of fewer persons to placebo or poten-
tially ineﬀective treatments, and facilitate subject
recruitment and retention.
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